At a glance

Most Recent Events

23 Nov 2016
Results published in the Gastroenterology

13 Jun 2016
Results published in a Shire media release.

13 Jun 2016
According to a Shire media release, the US FDA has granted Breakthrough Therapy Designation to oral budesonide suspension (SHP621) for eosinophinic esophagitis based on results from this trial.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login
with a username/password associated to an account with a valid subscription